R Charles Coombes Selected Research

irosustat

11/2017	IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.
9/2017	IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
7/2013	A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer.
2/2011	Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer.
3/2006	Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

R Charles Coombes Research Topics

Disease

115	Breast Neoplasms (Breast Cancer) 12/2021 - 09/2003
88	Neoplasms (Cancer) 12/2021 - 01/2002
13	Neoplasm Metastasis (Metastasis) 01/2019 - 08/2005
5	Circulating Neoplastic Cells 01/2017 - 02/2011
3	Triple Negative Breast Neoplasms 08/2015 - 03/2007
3	Carcinogenesis 01/2014 - 10/2003
2	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2021 - 09/2008
2	Lymphatic Metastasis 01/2019 - 08/2005
2	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 02/2008
2	Carcinoma (Carcinomatosis) 06/2017 - 01/2014
2	Prostatic Neoplasms (Prostate Cancer) 03/2014 - 12/2011
2	Residual Neoplasm 02/2012 - 03/2005
2	Infections 01/2012 - 11/2006
2	Necrosis 06/2008 - 11/2006
2	Bone Resorption 02/2008 - 02/2007
2	Neoplasm Micrometastasis 08/2005 - 03/2005
1	Pancreatic Neoplasms (Pancreatic Cancer) 12/2021

Drug/Important Bio-Agent (IBA)

27	Estrogen ReceptorsIBA 09/2021 - 12/2003
18	Proteins (Proteins, Gene)FDA Link 12/2016 - 01/2002
17	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2002
16	Tamoxifen FDA LinkGeneric 05/2019 - 09/2003
12	DNA (Deoxyribonucleic Acid)IBA 07/2021 - 09/2006
11	Pharmaceutical PreparationsIBA 07/2019 - 04/2004
11	Aromatase InhibitorsIBA 09/2017 - 09/2003
11	Estrogen Receptor alphaIBA 07/2015 - 12/2004
10	Messenger RNA (mRNA)IBA 04/2021 - 10/2003
9	Biological ProductsIBA 01/2017 - 01/2002
8	Hormones (Hormone)IBA 01/2021 - 08/2005
8	exemestane (Aromasin)FDA Link 05/2019 - 03/2004
7	Cell-Free Nucleic AcidsIBA 01/2021 - 02/2012
6	Transcription Factors (Transcription Factor)IBA 01/2018 - 01/2006
6	Estrogens (Estrogen)FDA Link 06/2014 - 12/2003
5	Steryl-Sulfatase (Steroid Sulfatase)IBA 11/2017 - 03/2006
5	irosustatIBA 11/2017 - 03/2006
5	Docetaxel (Taxotere)FDA Link 04/2012 - 02/2008
4	Peptides (Polypeptides)IBA 11/2017 - 01/2006
4	Paclitaxel (Taxol)FDA LinkGeneric 06/2017 - 12/2003
4	Epirubicin (Ellence)FDA LinkGeneric 07/2013 - 06/2005
4	Histone Deacetylase InhibitorsIBA 10/2006 - 01/2002
4	theasinensin AIBA 10/2006 - 12/2004
3	LigandsIBA 12/2021 - 12/2003
3	ZincIBA 12/2021 - 01/2015
3	MicroRNAs (MicroRNA)IBA 10/2021 - 05/2013
3	Phenobarbital (Luminal)FDA Link 04/2021 - 09/2015
3	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 01/2002
3	Small Interfering RNA (siRNA)IBA 06/2017 - 07/2009
3	AntigensIBA 02/2017 - 01/2006
3	Phosphotransferases (Kinase)IBA 04/2012 - 01/2006
3	Choline (Choline Chloride)IBA 12/2011 - 09/2009
3	ErbB Receptors (EGF Receptor)IBA 09/2011 - 06/2005
3	Trastuzumab (Herceptin)FDA Link 04/2011 - 07/2010
3	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 01/2010 - 09/2006
3	Gefitinib (Iressa)FDA Link 03/2009 - 06/2005
3	Anastrozole (Arimidex)FDA LinkGeneric 02/2008 - 09/2003
3	trichostatin A (A 300)IBA 10/2006 - 12/2004
3	Cyclin D1IBA 02/2006 - 12/2004
2	IsotopesIBA 12/2021 - 01/2021
2	Progesterone Receptors (Progesterone Receptor)IBA 09/2021 - 09/2009
2	Cadherins (E-Cadherin)IBA 04/2021 - 01/2019
2	Cytosine DeaminaseIBA 01/2021 - 11/2017
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2017 - 07/2009
2	human ERBB2 proteinIBA 02/2017 - 08/2011
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2017 - 12/2010
2	ChromatinIBA 01/2016 - 10/2015
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 08/2015 - 05/2009
2	Monoclonal AntibodiesIBA 07/2015 - 11/2014
2	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 11/2014 - 10/2012
2	SteroidsIBA 03/2014 - 03/2006
2	Ion Channels (Ion Channel)IBA 03/2014 - 08/2005
2	Voltage-Gated Sodium ChannelsIBA 03/2014 - 08/2005
2	Indicators and Reagents (Reagents)IBA 01/2014 - 01/2007
2	Lapatinib (GW572016)FDA Link 01/2013 - 07/2009
2	EnzymesIBA 10/2012 - 03/2006
2	taxaneIBA 04/2012 - 08/2011
2	Forkhead Box Protein M1IBA 09/2011 - 01/2010
2	AnthracyclinesIBA 08/2011 - 02/2008
2	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2011 - 04/2004
2	Epidermal Growth Factor (EGF)IBA 07/2010 - 09/2009
2	Protein Isoforms (Isoforms)IBA 09/2008 - 10/2003
2	alovudineIBA 09/2007 - 11/2005
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2007 - 06/2005
2	UbiquitinIBA 02/2006 - 02/2006
2	Histone Deacetylases (Histone Deacetylase)IBA 01/2005 - 01/2002
1	MetalloproteinsIBA 12/2021
1	SulfurIBA 12/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2021
1	Hydroxyl RadicalIBA 12/2021
1	Tumor Biomarkers (Tumor Markers)IBA 11/2021
1	Celecoxib (Celebrex)FDA Link 09/2021
1	Circulating Tumor DNAIBA 01/2021
1	Alkaline PhosphataseIBA 12/2019
1	Zinc Oxide FDA Link 07/2019
1	Glutathione (Reduced Glutathione)IBA 07/2019
1	Silicon Dioxide (Silica)FDA LinkGeneric 07/2019
1	Aldo-Keto ReductasesIBA 01/2019

Therapy/Procedure

61	Therapeutics 10/2021 - 09/2003
14	Drug Therapy (Chemotherapy) 10/2021 - 09/2007
3	Aftercare (After-Treatment) 11/2009 - 03/2006
2	Immunotherapy 01/2014 - 01/2006
2	Adjuvant Chemotherapy 07/2010 - 11/2009